Quick Answer
Alto Neuroscience, Inc. reported Cash And Cash Equivalents At Carrying Value of $176.48 million for the year ending 2025.
- Alto Neuroscience, Inc. showed an increase of +4.9% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Alto Neuroscience, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2024: $205.90 million | Q2 2024: $193.12 million | Q3 2024: $181.70 million | Q1 2025: $160.75 million | Q2 2025: $147.59 million | Q3 2025: $137.82 million.
- Over the full 3 years of available data (2023 to 2025), Alto Neuroscience, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 113.8%.
- Historical annual values: Fiscal year 2025: $176.48 million | Fiscal year 2024: $168.23 million | Fiscal year 2023: $82.55 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: